Anti-inflammatory effects of ginsenosides from Panax ginseng and their structural analogs

African Journal of Biotechnology

Volumn 8, Issue 16, 2009, Pages 3682-3690

  Park, Jongsun ^a   Jae, Youl Cho ^b  

^a Chungnam National University   (South Korea)

^b Kangwon National University   (South Korea)

Author keywords

Ginseng saponin; Ginsenoside; Inflammation; Nitric oxide; Prostaglandin; Tumor necrosis factor

Indexed keywords

20 ORTHO BETA DEXTRO GLUCOPYRANOSYL 20 PROTOPANAXADIOL; 20 PROTOPANAXATRIOL; GINSENG EXTRACT; GINSENOSIDE; GINSENOSIDE RB 1; GINSENOSIDE RB 2; GINSENOSIDE RC; GINSENOSIDE RD; GINSENOSIDE RE; GINSENOSIDE RF; GINSENOSIDE RG 1; GINSENOSIDE RG 3; GINSENOSIDE RH 1; GINSENOSIDE RH 2; GINSENOSIDE RP 1; GINSENOSIDE RP 2; HERBIMYCIN; METHYLPREDNISOLONE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PICLAMILAST; PREDNISOLONE; PROSTAGLANDIN E2; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; ROLIPRAM; SPHINGOSINE; STAUROSPORINE; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CONCENTRATION RESPONSE; CONTACT DERMATITIS; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; GINSENG; IC 50; IMMUNOPATHOGENESIS; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; INNATE IMMUNITY; KIDNEY INJURY; LIVER INJURY; NEUROPROTECTION; NONHUMAN; PASSIVE SKIN ANAPHYLAXIS; PROSTAGLANDIN SYNTHESIS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SEPTIC SHOCK;

PANAX GINSENG;

EID: 70349182370     PISSN: None     EISSN: 16845315     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Alexander B (1998). The role of nitric oxide in hepatic metabolism. Nutrition, 14: 376-390. (Pubitemid 28222237)
2. Bae EA, Han MJ, Choo MK, Park SY, Kim DH (2002). Metabolism of 20(S) and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities. Biol. Pharm. Bull. 25: 58-63.
3. Bae EA, Han MJ, Shin YW, Kim DH (2006a) Inhibitory effects of Korean red ginseng and its genuine constituents ginsenosides Rg3, Rf, and Rh2 in mouse passive cutaneous anaphylaxis reaction and contact dermatitis models. Biol. Pharm. Bull. 29: 1862-1867.
4. Bae EA, Kim EJ, Park JS, Kim HS, Ryu JH, Kim DH (2006b). Ginsenosides Rg3 and Rh2 inhibit the activation of AP-1 and protein kinase A pathway in lipopolysaccharide/interferon-gammastimula-ted BV-2 microglial cells. Planta Med. 72: 627-633.
5. Bermudez LE (1994). Immunobiology of Mycobacterium avium infection. Eur. J. Clin. Microbiol. Infect Dis. 13: 1000-1006.
6. Bluethmann H, Rothe J, Schultze N, Tkachuk M, Koebel P (1994). Establishment of the role of IL-6 and TNF receptor 1 using gene knockout mice. J. Leukoc Biol. 56: 565-570. (Pubitemid 24348813)
7. Burrage PS, Mix KS, Brinckerhoff CE (2006). Matrix metalloproteinases: role in arthritis. Front Biosci. 11: 529-543.
8. Byeon SE, Lee YG, Kim JC, Han JG, Lee HY, Cho JY (2008). Hinokitiol, a Natural Tropolone Derivative, Inhibits TNF-alpha Production in LPS-Activated Macrophages via Suppression of NF-κB. Planta Med. 74: 828-833.
9. Chiarugi V, Magnelli L, Gallo O (1998). Cox-2, iNOS and p53 as playmakers of tumor angiogenesis (review). Int. J. Mol. Med. 2: 715-719.
10. Cho JY, Nam KH, Kim AR, Park J, Yoo ES, Baik KU, Yu YH, Park MH (2001a). In-vitro and in-vivo immunomodulatory effects of syringin. J. Pharm. Pharmacol. 53: 1287-1294.
11. Cho JY, Park JS, Baik KU, Lee JG, Kim HP, Yoo ES, Park MH (2004). Differential effect of phosphodiesterase IV inhibitor RP73401 on various inflammatory and immune responses relevent to rheumatoid arthritis. Pharmacol. Res. 49: 423-431.
12. Cho JY, Yeon JD, Kim JY, Yoo ES, Yu YH, Park MH (2000). Hepatoprotection by human epidermal growth factor (hEGF) against experimental hepatitis induced by D-galactosamine (D-galN) or D-GalN/ lipopolysaccharide. Biol. Pharm. Bull. 23: 1243-1246.
13. Cho JY, Yoo ES, Baik KU, Park MH, Han BH (2001b). In vitro inhibitory effect of protopanaxadiol ginsenosides on tumor necrosis factor (TNF)-alpha production and its modulation by known TNF-alpha antagonists. Planta Med. 67: 213-218.
14. Cho MK, Sakurai H, Kim DH, Saiki I (2008). A ginseng saponin metabolite suppresses tumor necrosis factor-alpha-promoted metastasis by suppressing nuclear factor-κB signaling in murine colon cancer cells. Oncol. Rep. 19: 595-600.
15. Deschoolmeester ML, Else KJ (2002). Cytokine and chemokine responses underlying acute and chronic Trichuris muris infection. Int. Rev. Immunol. 21: 439-467.
16. Freeman BD, Buchman TG (2001) Interleukin-1 receptor antagonist as therapy for inflammatory disorders. Expert. Opin. Biol. Theor. 1: 301-308.
17. Fujihara M, Muroi M, Tanamoto K, Suzuki T, Azuma H, Ikeda H (2003). Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacol. Theor. 100: 171-194.
18. Glauser MP (1996). The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock. Drugs, 52(2): 9-17.
19. Gordon S (1998). The role of the macrophage in immune regulation. Res. Immunol. 149: 685-688.
20. Hasegawa H (2004). Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. J. Pharmacol. Sci. 95: 153-157.
21. Hasegawa H, Sung JH, Benno Y (1997). Role of human intestinal Prevotella oris in hydrolyzing ginseng saponins. Planta Med. 63: 436-440. (Pubitemid 27399983)
22. Hong S, Kim SH, Rhee MH, Kim AR, Jung JH, Chun T, Yoo ES, Cho JY (2003). In vitro anti-inflammatory and pro-aggregative effects of a lipid compound, petrocortyne A, from marine sponges. Naunyn Schmiedebergs Arch Pharmacol. 368: 448-456.
23. Kang KS, Kim HY, Yamabe N, Park JH, Yokozawa T (2007). Preventive effect of 20(S)-ginsenoside Rg3 against lipopolysac-charide-induced hepatic and renal injury in rats. Free Radic Res. 41: 1181-1188. (Pubitemid 47470856)
24. Kim BH, Cho JY (2008). Anti-inflammatory effect of honokiol is mediated by PI3K/Akt pathway suppression. Acta Pharmacol. Sin. 29: 113-122.
25. Kim HA, Kim S, Chang SH, Hwang HJ, Choi YN (2007). Anti-arthritic effect of ginsenoside Rb1 on collagen induced arthritis in mice. Int. Immunopharmacol. 7: 1286-1291.
26. Kirkeboen KA, Strand OA (1999). The role of nitric oxide in sepsis-an overview. Acta Anaesthesiol. Scand. 43: 275-288.
27. Lee YG, Lee WM, Kim JY, Lee JY, Lee IK, Yun BS, Rhee MH, Cho JY (2008). Src kinase-targeted anti-inflammatory activity of davallialactone from Inonotus xeranticus in lipopolysaccharide-activated RAW264.7 cells. Br. J. Pharmacol. 154: 852-863.
28. Levite M, Chowers Y (2001). Nerve-driven immunity: neuropeptides regulate cytokine secretion of T cells and intestinal epithelial cells in a direct, powerful and contextual manner. Ann. Oncol. 12(2): S19-25.
29. Lin WM, Zhang YM, Moldzio R, Rausch WD (2007). Ginsenoside Rd attenuates neuroinflammation of dopaminergic cells in culture. J. Neural Transm Suppl. pp. 105-112.
30. Liu CX, Xiao PG (1992). Recent advances on ginseng research in China. J. Ethnopharmacol. 36: 27-38.
31. Lorenz HM (2000) TNF inhibitors in the treatment of arthritis. Curr. Opin. Investig. Drugs. 1: 188-193.
32. Lorenz HM, Herrmann M, Kalden JR (2001). The pathogenesis of autoimmune diseases. Scand J. Clin. Lab. Invest Suppl. 235: 16-26.
33. MacMicking J, Xie QW, Nathan C (1997). Nitric oxide and macro-phage function. Ann. Rev. Immunol. 15: 323-350.
34. Maddox L, Schwartz DA (2002). The pathophysiology of asthma. Ann. Rev. Med. 53: 477-498.
35. Martel-Pelletier J, Pelletier JP, Fahmi H (2003). Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum, 33: 155-167.
36. Medzhitov R, Janeway Jr. CA (1998). Innate immune recognition and control of adaptive immune responses. Semin Immunol. 10: 351-353. (Pubitemid 28499548)
37. Murakami A, Ohigashi H (2007). Targeting NOX, INOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals. Int. J. Cancer. 121: 2357-2363.
38. Naumann M (2000). Nuclear factor-κB activation and innate immune response in microbial pathogen infection. Biochem. Pharmacol. 60: 1109-1114.
39. Oh GS, Pae HO, Choi BM, Seo EA, Kim DH, Shin MK, Kim JD, Kim JB, Chung HT (2004). 20(S)-Protopanaxatriol, one of ginsenoside metabolites, inhibits inducible nitric oxide synthase and cyclooxygenase- 2 expressions through inactivation of nuclear factor-κB in RAW 264.7 macrophages stimulated with lipopolysaccharide. Cancer Lett. 205: 23-29.
40. Ortaldo JR (1991). Human cytotoxic effector cells: definition and analysis of activity. Allergol Immunopathol (Madr). 19: 145-156.
41. Ovary Z (1982). Recent insight into class-specific properties of murine immunoglobulins obtained with the help of monoclonal antibodies. Int. Arch Allergy Appl. Immunol. 69: 385-392.
42. Park EK, Shin YW, Lee HU, Kim SS, Lee YC, Lee BY, Kim DH (2005). Inhibitory effect of ginsenoside Rb1 and compound K on NO and prostaglandin E2 biosyntheses of RAW264.7 cells induced by lipopolysaccharide. Biol. Pharm. Bull. 28: 652-656.
43. Park YC, Lee CH, Kang HS, Kim KW, Chung HT, Kim HD (1996). Ginsenoside-Rh1 and Rh2 inhibit the induction of nitric oxide synthesis in murine peritoneal macrophages. Biochem. Mol. Biol. Int. 40: 751-757.
44. Pass HI, Mew D, Pass HA, Temeck BK (1995). The macrophage, TNF, and other cytokines. Chest Surg. Clin. N Am. 5: 73-90.
45. Radi ZA, Kehrli ME, Jr., Ackermann MR (2001). Cell adhesion molecules, leukocyte trafficking, and strategies to reduce leukocyte infiltration. J. Vet. Int. Med. 15: 516-529.
46. Romas E, Gillespie MT, Martin TJ (2002). Involvement of receptor activator of NF-κB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone, 30: 340-346.
47. Sanchez-Madrid F, Gonzalez-Amaro R (2001). Drugs inflammation and cell adhesion receptors. Expert Opin. Pharmacother. 2: 3-17.
48. Shah V, Lyford G, Gores G, Farrugia G (2004). Nitric oxide in gastrointestinal health and disease. Gastroenterology, 126: 903-913.
49. Shibata S (2001). Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J. Korean Med. Sci. 16 Suppl: S28-37.
50. Shin YW, Bae EA, Kim SS, Lee YC, Kim DH (2005). Effect of ginsenoside Rb1 and compound K in chronic oxazolone-induced mouse dermatitis. Int Immunopharmacol. 5: 1183-1191. (Pubitemid 40731524)
51. Shinoda J, Whittle IR (2001). Nitric oxide and glioma: a target for novel therapy? Br. J. Neurosurg. 15: 213-220. (Pubitemid 32660955)
52. Sinkovics JG, Horvath JC (2005). Human natural killer cells: a comprehensive review. Int. J. Oncol. 27: 5-47.
53. Spina D (2003). Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs. 63: 2575-2594. (Pubitemid 37491561)
54. Stancheva SL, Alova LG (1993). Ginsenoside Rg1 inhibits the brain cAMP phosphodiesterase activity in young and aged rats. Gen. Pharmacol. 24: 1459-1462.
55. Vervoordeldonk MJ, Tak PP (2002). Cytokines in rheumatoid arthritis. Curr. Rheumatol. Rep. 4: 208-217.
56. Vujanovic NL (2001). Role of TNF family ligands in antitumor activity of natural killer cells. Int. Rev. Immunol. 20: 415-437.
57. Wu CF, Bi XL, Yang JY, Zhan JY, Dong YX, Wang JH, Wang JM, Zhang R, Li X (2007). Differential effects of ginsenosides on NO and TNFalpha production by LPS-activated N9 microglia. Int. Immunopharmacol. 7: 313-320.
58. Zanotti S, Kumar A, Kumar A (2002) Cytokine modulation in sepsis and septic shock. Expert Opin. Investig. Drugs, 11: 1061-1075.